Drug intelligence / Profile preview

FID123300

Development stage: Unknown
Lead developer: Alcon
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems
Administration: Ophthalmic

Overview

FID123300 is an investigational **ocular lubricant** being developed for the treatment of **dry eye disease** and **Sjogren's syndrome**. It is intended to improve lubrication of the ocular surface, potentially relieving symptoms such as dryness and irritation. The detailed mechanism of action, including molecular targets, has not been disclosed. The formulation is being evaluated in at least one clinical trial for safety and performance over a 30-day period in adult patients with mild to moderate dry eye disease.

Beyond the preview

Go deeper on FID123300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FID123300.

Explore the full profile